Similar articles

• Infliximab cost-effectiveness/safety?

  Rothschild BM. Rothschild BM. Rheumatology (Oxford). 2003 Dec;42(12):1572-3; author reply 1573-4. doi: 10.1093/rheumatology/keg409. Rheumatology (Oxford). 2003. PMID: 14645868 No abstract available.
• Comment on: Modelling the cost effectiveness of TNF antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.

  van Vollenhoven RF; British Society for Rheumatology Biologics Registry. van Vollenhoven RF, et al. Rheumatology (Oxford). 2008 Jul;47(7):1106-7; author reply 1107. doi: 10.1093/rheumatology/ken105. Epub 2008 Mar 7. Rheumatology (Oxford). 2008. PMID: 18326533 No abstract available.
• Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands.

  Welsing PM, Severens JL, Hartman M, van Riel PL, Laan RF. Welsing PM, et al. Arthritis Rheum. 2004 Dec 15;51(6):964-73. doi: 10.1002/art.20843. Arthritis Rheum. 2004. PMID: 15593319
• Rituximab (Rituxan) for rheumatoid arthritis.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2006 Apr 24;48(1233):34-5. Med Lett Drugs Ther. 2006. PMID: 16625143 Review. No abstract available.
• A clinician's critique of rheumatoid arthritis health economic models.

  Jobanputra P. Jobanputra P. Rheumatology (Oxford). 2011 Sep;50 Suppl 4:iv48-iv52. doi: 10.1093/rheumatology/ker246. Rheumatology (Oxford). 2011. PMID: 21859706 Review.